¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"insulin like activity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • insulin-to-glucose ratio
    Àν¶¸°´ëÆ÷µµ´çºñ
  • intermediate-acting insulin
    Áß°£ÀÛ¿ëÀν¶¸°
  • long acting insulin
    Áö¼ÓÀÛ¿ëÀν¶¸°
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • NPH insulin
    NPHÀν¶¸°
  • purified insulin
    ¼ø¼öÀν¶¸°, Á¤Á¦Àν¶¸°
  • regular insulin
    ¼ÓÈ¿Àν¶¸°, ºü¸¥ÀÛ¿ëÀν¶¸°
  • suppressive insulin
    ¾ïÁ¦Àν¶¸°
  • short acting insulin
    ´Ü±âÀÛ¿ëÀν¶¸°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • reflex gamma activity
    ¹Ý»ç°¨¸¶È°µ¿
  • sexual activity
    ¼ºÈ°µ¿
  • specific activity
    ºñ¹æ»ç´É, ƯÀÌȰ¼ºµµ
  • spontaneous activity
    ÀÚ¹ßÀüÀ§
  • time-activity curve
    ½Ã°£¹æ»ç´É°î¼±
  • professional activity study
    Àü¹®°¡È°µ¿¿¬±¸
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • sperm activity grade test
    Á¤Àڿµî±Þ°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
  • insulin shock treatment
    Àν¶¸°Ãæ°ÝÄ¡·á.
  • insulin test
    Àν¶¸°½ÃÇè.
  • insulin therapy
    Àν¶¸°Ä¡·á, Àν¶¸°¿ä¹ý.
  • insulin tolerance
    Àν¶¸°³»¼º.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè
  • protamin insulin(e)
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) insulin
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • activity
    ¹æ»ç´É, Ȱ¼ºµµ
  • activity
    Ȱ¼ºµµ(üÀàõöô), Ȱµ¿µµ(üÀÔÑöô), Ȱ¼º(üÀàõ).
  • activity therapist
    Ȱµ¿ ¿ä¹ý»ç
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity, antibacterial
    Ç×±ÕÀÛ¿ë
  • amylase activity
    ¾Æ¹Ð¶óÁ¦-Ȱ¼ºµµ
  • antibacterial activity
    Ç×±ÕÀÛ¿ë(ù÷жíÂéÄ), Ç×±ÕȰ¼º(ù÷жüÀàõ).
  • bacteri(o)cidal activity
    »ì±Õ·Â.
  • binding activity
    °áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding activity
    ¸é¿ª°áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • caries activity
    ¿ì½ÄȰµ¿¼º(ó»ãÚüÀÔÑàõ), ¿ì½ÄȰµ¿µµ(¡­öô).
  • displacement activity
    ÀüġȰµ¿
  • effect concentration(=activity)
    À¯È¿³óµµ(êóüùÒØÓø)
  • elastolytic activity
    ¿¤¶ó½ºÆ¾¿ëÇØÈ°¼º(µµ), ¿¤¶ó½ºÅ¸¾ÆÁ¦È°¼º(µµ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IRI immunoreactive insulin; insulin resistance index
IRS immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub...
IST inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci...
ELA elastase; elastomer-lubricating agent; endotoxin-like activity
RFLA rheumatoid-factor-like activity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IGFBP-5 Insulin-like growth factor binding protein 5
IGFBP-3 Insulin-like growth factor binding protein-3
IGFBP-1 Insulin-like growth factor (IGF)-binding protein 1
IGFBP-3 Insulin-like growth factor (IGF)-binding protein-3
IGF-BP insulin-like growth factor I and its binding protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maintained activity
    Ȱ¼º À¯Áö
  • mask-like face
    °¡¸é»ó ¾È¸é
  • mental activity
    Á¤½Å Ȱµ¿
  • molar activity
    ¸ô Ȱ¼º
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • muscle activity
    ±Ù Ȱ¼º
  • muscular activity
    ±ÙÀ° Ȱµ¿, ±Ù Ȱ¼ºµµ
  • needle-like shape
    ħÇü
  • neuromuscular reflex activity
    ±Ù½Å°æ ¹Ý»ç Ȱµ¿
  • nociceptor activity
    Ä§ÇØ ¼ö¿ëü Ȱ¼º, À¯ÇØ ¼ö¿ë±â Ȱ¼º
  • partial agonistic activity
    ºÎºÐ È¿´É, ºÎºÐ È¿´ÉÀû Ȱ¼º, ºÎºÐ È¿ÇöÀû Ȱ¼º
  • persistent activity
    Áö¼ÓÀûÀΠȰ¼º
  • pertussis-like syndrome
    ¹éÀÏÇØ¾ç ÁõÈıº
    ÀÓ»óÀûÀ¸·Î ¹éÀÏÇØ¿Í ±¸º°ÀÌ µÇÁö ¾Ê´Â ÁõÈıºÀ¸·Î¼­, Bordetella
  • petechia-like lesion
    Á¡»ó ÃâÇ÷ °°Àº º´¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
Rhabditis-like See: rhabditiform larva.
(05 Mar 2000)
messenger-like RNA An ill-defined form of RNA, of high molecular weight, that never leaves the nucleus and is thought to be the precursor of messenger RNA.
(05 Mar 2000)
ring-like corneal dystrophy Thread-like opacities of the anterior corneal stroma, with acute, painful onset followed by decreased vision; autosomal dominant inheritance.
(05 Mar 2000)
pertussis-like syndrome <syndrome> A syndrome characterised by severe episodes of coughing resembling whooping cough (pertussis).
(05 Mar 2000)
rosacea-like tuberculid Papular lesions in rosacea, characterised microscopically by perifollicular granulomas with central necrosis and scattered giant cells. Lupus miliaris disseminatus faciei is probably a form of granulomatous rosacea.
Synonym: rosacea-like tuberculid, tuberculoid rosacea.
(05 Mar 2000)
pleuropneumonia like organism Very tinymicroorganisms (usually spherical with a diameter of 0.3 to 0.8 micrometres, the smallest cells known) which are able to slip through most filters andare therefore often found as contaminating organisms in cultures, vaccines and other supposedly sterile preparations. Some types of mycoplasmas cause pneumonia. Mycoplasmal contamination is an important problem in biotechnology, but fortunately the microbes can usually be killed with antibiotics.
(09 Oct 1997)
pleuropneumonia-like organisms The original name given to a group of bacteria which did not possess cell walls; these organism's, isolated from man and other animals, soil, and sewage, are now assigned to the order Mycoplasmatales.
(05 Mar 2000)
corticotropin-like intermediate-lobe peptide <protein> A product of propiomelanocortin with unknown function.
Acronym: CLIP
(05 Mar 2000)
Csk-like protein-tyrosine kinase <enzyme> Phosphorylates c-terminal conserved tyr of src family members; from mouse brain; has 52% identity with mouse csk; mw 52 kD; genbank u05210
Registry number: EC 2.7.1.-
Synonym: ctk (kinase), ctk gene product, csk-type protein-tyrosine kinase, ntk (kinase), bhk (kinase)
(26 Jun 1999)
cyanobacterium-like bodies A Cryptosporidium-like genus of coccidian parasites reported from millipedes, reptiles, insectivores, and a rodent species. Cyclospora is characterised by acid-fast oocysts with two sporocysts, each with two sporozoites. Cyclospora species is an undescribed but distinct species of Cyclospora that is implicated as the cause of a widespread, prolonged but self-limited human diarrhoea in patients in North, Central, and South America; Caribbean countries; Southeast Asia; and eastern Europe previously reported as caused by cyanobacterium-like bodies.
Synonym: cyanobacterium-like bodies.
(05 Mar 2000)
hepatitis c-like viruses A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species.
(12 Dec 1998)
Shiga like toxin <protein> Group of structurally related toxins that block eukaryotic protein synthesis by cleaving the 28S rRNA subunit of ribosomes.
Examples: Shiga toxin, Shiga like toxins SLT 1 and SLT 2 of Escherichia coli.
(18 Nov 1997)
SLE-like syndrome <syndrome> A disease with manifestations suggestive of systemic lupus erythematosus, without meeting diagnostic criteria for that disease; sometimes used for drug-induced lupus.
(05 Mar 2000)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
thogoto-like viruses A genus of the family orthomyxoviridae comprising tick-borne viruses occasionally infecting humans. Dhori and thogoto viruses were formerly thought to be members of bunyaviridae. Thogoto virus is the type species.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á